|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
WO1989007142A1
(en)
|
1988-02-05 |
1989-08-10 |
Morrison Sherie L |
Domain-modified constant region antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
EP0826696B1
(de)
|
1996-09-03 |
2002-05-29 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
|
|
HUP0100813A3
(en)
|
1998-02-25 |
2003-08-28 |
Lexigen Pharmaceuticals Corp L |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US7112324B1
(en)
|
1998-04-21 |
2006-09-26 |
Micromet Ag |
CD 19×CD3 specific polypeptides and uses thereof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
PT1974747E
(pt)
|
1998-08-11 |
2012-09-05 |
Biogen Idec Inc |
Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
|
AU2002250293B2
(en)
|
2001-03-09 |
2007-10-11 |
Arnason, Barry G. Mr |
Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
|
|
WO2003026490A2
(en)
|
2001-09-28 |
2003-04-03 |
Elusys Therapeutics, Inc. |
Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
WO2003068821A2
(en)
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
|
EP1400534B1
(en)
|
2002-09-10 |
2015-10-28 |
Affimed GmbH |
Human CD3-specific antibody with immunosuppressive properties
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
BRPI0315295C1
(pt)
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
CN1802388B
(zh)
|
2003-05-09 |
2011-01-05 |
杜克大学 |
Cd20特异抗体及使用它们的方法
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
RU2005137325A
(ru)
|
2003-05-31 |
2006-09-10 |
Микромет Аг (De) |
Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
|
|
DK1629011T3
(da)
|
2003-05-31 |
2010-05-03 |
Micromet Ag |
Humane anti-humane-DC3-bindingsmolekyler
|
|
NZ544924A
(en)
|
2003-06-27 |
2009-03-31 |
Biogen Idec Inc |
Modified binding molecules comprising connecting peptides
|
|
MXPA06002134A
(es)
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
KR20060107555A
(ko)
|
2003-12-19 |
2006-10-13 |
제넨테크, 인크. |
이식 거부에서 ｃｄ20의 검출
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
ZA200608982B
(en)
|
2004-05-05 |
2008-06-25 |
Genentech Inc |
Preventing autoimmune disease by using an anti-CD20 antibody
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
MXPA06014067A
(es)
|
2004-06-04 |
2007-02-15 |
Genentech Inc |
Metodo para tratar lupus.
|
|
BRPI0516297A
(pt)
|
2004-10-05 |
2008-09-02 |
Genentech Inc |
métodos de tratamento de vasculite e artigos de fabricação
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
|
US20120189643A1
(en)
|
2004-11-30 |
2012-07-26 |
Carton Jill M |
Toll Like Receptor 3 Antagonists, Methods and Uses
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
ZA200708857B
(en)
|
2005-04-22 |
2009-01-28 |
Genentech Inc |
Method for treating dementia or alzheimer's disease with a CD30 antibody
|
|
JP2008541758A
(ja)
|
2005-06-02 |
2008-11-27 |
アストラゼネカ エービー |
Ｃｄ２０に対する抗体およびその使用
|
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
|
NZ612578A
(en)
|
2005-08-19 |
2014-11-28 |
Abbvie Inc |
Dual variable domain immunoglobin and uses thereof
|
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
|
SG10201400426XA
(en)
|
2006-01-12 |
2014-07-30 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
JP4294082B2
(ja)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
ES2593484T3
(es)
|
2007-03-29 |
2016-12-09 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
|
MX2009010611A
(es)
|
2007-04-03 |
2010-03-26 |
Micromet Ag |
Enlazadores biespecificos, especificos para especies.
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
EP2158318A2
(en)
|
2007-05-14 |
2010-03-03 |
Biogen Idec MA, Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
ES2623925T3
(es)
|
2007-05-30 |
2017-07-12 |
Postech Academy-Industry- Foundation |
Proteínas de fusión de inmunoglobulina
|
|
JP5511654B2
(ja)
|
2007-05-31 |
2014-06-04 |
ゲンマブ エー／エス |
分子操作により得られた組換え非グリコシル化一価半抗体
|
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー／エス |
安定なＩｇＧ４抗体
|
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
MX2010000970A
(es)
|
2007-07-31 |
2010-03-09 |
Regeneron Pharma |
Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
|
|
MX2010001395A
(es)
|
2007-08-10 |
2010-03-10 |
Regeneron Pharma |
Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
|
|
AU2008295140A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
MX2010003329A
(es)
|
2007-09-26 |
2010-04-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de il-6.
|
|
RU2010138612A
(ru)
|
2008-02-20 |
2012-03-27 |
Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
|
|
WO2009106096A1
(en)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Treatment of resistant tumors with trifunctional antibodies
|
|
EP2356154A4
(en)
|
2008-11-06 |
2012-12-19 |
Alexion Pharma Inc |
DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
|
|
PL2918604T3
(pl)
|
2008-11-07 |
2018-05-30 |
Amgen Research (Munich) Gmbh |
Leczenie pediatrycznej ostrej białaczki limfoblastycznej
|
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
JP2012515556A
(ja)
|
2009-01-23 |
2012-07-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2826789A1
(en)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
US8961967B2
(en)
|
2009-11-30 |
2015-02-24 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
|
CA2785907A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
BR112012027917A2
(pt)
|
2010-04-30 |
2017-11-28 |
Alexion Pharma Inc |
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
|
|
EP2585828A4
(en)
|
2010-06-25 |
2014-03-12 |
Glaxo Group Ltd |
METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
KR101871008B1
(ko)
|
2010-09-16 |
2018-06-25 |
발리오팜 아게 |
항-huTNFR1 항체
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
ES2623912T3
(es)
|
2010-12-23 |
2017-07-12 |
Janssen Biotech, Inc. |
Mutantes FC de anticuerpo activo resistente a proteasa
|
|
PT2673373T
(pt)
|
2011-02-08 |
2018-12-05 |
Medimmune Llc |
Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013112986A1
(en)
|
2012-01-27 |
2013-08-01 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
|
WO2013157105A1
(ja)
|
2012-04-18 |
2013-10-24 |
公立大学法人大阪市立大学 |
ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
|
|
MX2014014891A
(es)
|
2012-06-05 |
2015-06-17 |
Regeneron Pharma |
Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
|
|
AU2013289883B2
(en)
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
WO2015006749A2
(en)
|
2013-07-12 |
2015-01-15 |
Zymeworks Inc. |
Bispecific cd3 and cd19 antigen binding contructs
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
EP3083696B1
(en)
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
AU2016325630B2
(en)
|
2015-09-23 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-CD3 bispecific antibodies and uses thereof
|
|
AU2016378573A1
(en)
*
|
2015-12-22 |
2018-07-19 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
|
|
LT3394103T
(lt)
|
2015-12-22 |
2023-09-11 |
Regeneron Pharmaceuticals, Inc. |
Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
|
|
EP3252078A1
(en)
*
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
JP7066690B2
(ja)
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｍｕｃ１６（ムチン１６）抗体
|
|
MY199468A
(en)
|
2016-09-23 |
2023-10-31 |
Regeneron Pharma |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
|
JP7784795B2
(ja)
*
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
KR102692708B1
(ko)
*
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
TW202504917A
(zh)
|
2018-06-21 |
2025-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
|
|
CA3110513A1
(en)
*
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
KR20230047214A
(ko)
|
2019-07-26 |
2023-04-06 |
벨로3디, 인크. |
3차원 물체 형상화에 대한 품질 보증
|